All In Biotech

Drug Trial Radar · NCT06614751

A PARG Inhibitor DAT-2645 Monotherapy in Patients with Advanced/Metastatic Solid Tumors Harboring BRCA1/2 Loss of Function Alterations And/or Other Defects in the DDR Pathway

A Phase I, Open-label, Dose Escalation and Dose Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of DAT-2645 in Patients with Advanced/Metastatic Solid Tumors Harboring BRCA1/2 Loss of Function Alterations And/or Other Defects in the DNA Damage Repair Pathway

Last checked: Nov 19, 2026Latest source record: Sep 27, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

112

Planned (sponsor's estimate)

Start

Nov 1, 2024

Primary completion

Nov 1, 2026

Study completion Jun 1, 2027

Sponsor

Sponsor type
Industry
First posted
Sep 26, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of the study is to evaluate the safety, tolerability, PK, PD, and prilimary efficacy of a PARG inhibitor DAT-2645 in patients with advanced/metastatic solid tumors harboring BRCA1/2 loss of function alterations and/or other defects in the DNA damage repair (DDR) pathway.

Conditions

  • Solid Cancers
  • BRCA Mutation
  • HRD Cancer
  • Breast Cancer
  • Prostate Cancer
  • Colorectal Cancer
  • Pancreatic Cancer
  • Endometrial Cancer
  • Gastric Cancer
  • Advanced Cancer
  • Metastatic Solid Tumors

Interventions

  • DAT-2645 tabletDrug

    The patient will be randomized into 2 groups and take DAT-2645 tablet daily. dosage is optimal dose-1 or optimal dose-2, 21day/ Cycle. The subject of this part is to optimize dosage and definite RP2D.

  • DAT-2645 tabletDrug

    The study set 6 dose level cohorts in dose escalation part.On C0D1, patient take DAT-2645 one time (Single use), The dosage is same as his enrolled cohort dose level. if no DLT, 7 days later(C1D1), patients will continue taking DAT-2645 tablet daily, dasage is same as before, 21days/cycle.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part 1, Dose esclalation study:To characterize the safety and tolerability of DAT-2645 monotherapy by evaluating the number of participants with dose limiting toxicities, adverse events, and laboratory abnormalities as graded by NCI CTCAE version 5.0Time frame: 6 months
  2. Part 2, Dose expansion study: To evaluate preliminary preliminary anti-tumor activity of DAT-2645 tablet monotherapy in participants by measuring tumor Overall Response Rate using RECIST criteria v1.1Time frame: Approximately 2 years

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Peking University Cancer Hospital and Institute

    Beijing, Beijing Municipality, China

  • Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College

    Beijjing, Beijing Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.